Skip to main content

Table 2 Risk factors by severity n (%)

From: The age again in the eye of the COVID-19 storm: evidence-based decision making

  Mild Moderate Severe
n (%) n (%) n (%)
Age (p = 0.046)
 < 30 0(0) 7(87.5) 1(12.5)
 30–45 3(13) 16(69.6) 4(17.4)
 45–60 12(19.7) 36(59) 13(21.3)
 60–75 9(10.1) 45(50.6) 35(39.3)
 > 75 13(17.1) 35(46.1) 28(36.8)
Gender (p = 0.049)
 Male 21(14.2) 73(49.3) 54(36.5)
 Female 16(14.7) 66(60.6) 27(24.8)
Hypertension
 No 15(12) 74(59.2) 36(28.8)
 Yes 19(15.7) 59(48.8) 43(35.5)
ACEIa intake
 No 6(8) 42(56.8) 26(35.1)
 Yes 7(20) 15(42.9) 13(37.1)
ARBb intake
 No 8(11) 37(50.7) 28(38.4)
 Yes 4(11.1) 19(52.8) 13(36.1)
Dyslipidaemia
 No 19(13.3) 84(58.7) 40(28)
 Yes 13(12.7) 49(48) 40(39.2)
Statins intake
 No 19(12.8) 88(59.1) 42(28.2)
 Yes 9(11.3) 39(48.8) 32(40)
Diabetes
 No 23(12.9) 102(57.3) 53(29.8)
 Yes 9(13.2) 33(48.5) 26(38.2)
Obesity
 No 20(12) 95(56.9) 52(31.1)
 Yes 3(8.8) 17(50) 14(41.2)
Primary Immunodeficiency
 No 27(11.6) 130(55.8) 76(32.6)
 Yes 0(0) 2(100) 0(0)
Secondary Immunodeficiency
 No 23(12.4) 103(55.7) 59(31.9)
 Yes 3(7.3) 24(58.5) 14(34.1)
Epidemiological background (p = 0.001)
 Nursing home resident 2(5.6) 19(52.8) 15(41.7)
 Live-in relative 10(19.2) 37(71.2) 5(9.6)
 Frontline worker 0(0) 11(78.6) 3(21.4)
 Community transmission 6(14.3) 16(38.1) 20(47.6)
  1. Abbreviations: ACEIa Angiotensin-converting enzyme inhibitors, ARBb Angiotensin II receptor blockers